Result: Single compensatory mutations were not detected in the switch therapy group; however,
rtQ215H/P/S +-
rtV214A/P mutations were found in 12 out of 88 patients (14%) in the add-on therapy group, and this difference was significant (P < 0.01).
Discussion: Accordingly, in our previously published report, we found that
rtQ215A/H/P/S substitutions could be detected as naturally occurring mutations in treatment-naive patients with
CHB.
Discussion: Further,
rtQ215S and
rtV214A mutations were compensatory mutations arising from ADV treatment.|mg